HER2 alterations across solid tumors: implications for comprehensive testing

This study highlights ERBB2 alterations across diverse cancers, demonstrating their heterogeneity and clinical significance. ERBB2 mutation-carrying tumors are less likely to have HER2 protein 3+ expression or CN amplification, indicating the need for comprehensive genomic analysis to identify those patients. In the context of pan-tumor approval of T-DXd for HER2, findings support integrating genomic and phenotypic data to enhance diagnostic precision and inform therapeutic decision-making. Comprehensive ERBB2 (HER2) testing across tumor types is essential to expand access to HER2-targeted therapies.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2025-08-16
DOI
https://doi.org/10.1093/oncolo/oyaf258
Citations
1
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
1.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HER2 alterations across solid tumors: implications for comprehensive testing

Arnab Basu, M. Midhun, Chinmay Jani, Tyler Mattox et al.
1 citations
The Oncologist
HER2/EGFR in Cancer Research
1.05
article

HER2 alterations across solid tumors: implications for comprehensive testing

Arnab Basu, M. Midhun, Chinmay Jani, Tyler Mattox, Garima Gupta, Rebecca C. Arend, Cyntanna C. Hawkins, Yanis Boumber, Bassel F. El‐Rayes, Aakash Desai, Mehmet Akce, Sejong Bae, Ahmed Ismail, Nusrat Jahan
article en
1 citations

Abstract

This study highlights ERBB2 alterations across diverse cancers, demonstrating their heterogeneity and clinical significance. ERBB2 mutation-carrying tumors are less likely to have HER2 protein 3+ expression or CN amplification, indicating the need for comprehensive genomic analysis to identify those patients. In the context of pan-tumor approval of T-DXd for HER2, findings support integrating genomic and phenotypic data to enhance diagnostic precision and inform therapeutic decision-making. Comprehensive ERBB2 (HER2) testing across tumor types is essential to expand access to HER2-targeted therapies.

The OncologistVol. 30(9)
Eastern Virginia Medical School (US), University of Alabama at Birmingham (US), Caris Life Sciences (United States) (US), Sylvester Comprehensive Cancer Center (US), Old Dominion University (US)
Daiichi Sankyo Europe
Peace, Justice and strong institutions
Openalex Percentile: Top 19%
HER2/EGFR in Cancer Research
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

HER2 alterations across solid tumors: implications for comprehensive testing — Arnab Basu, M. Midhun, et al. · The Oncologist (2025) | TGRS Research Map | TGRS